Valeant Taking The Fight To Allergan Shareholders; Pearson Confident
This article was originally published in The Pink Sheet Daily
Executive Summary
Valeant has been engaging Allergan shareholders and intends to make its actions more formal. Meanwhile, Valeant CEO Pearson continues to be overly confident that the deal will get done.
You may also be interested in...
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
Update: Ziopharm Study Death Not Due To Drug
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.